Sun Pharmaceutical

  • Strides Shasun gets CCI nod to buy Sun Pharma’s two divisions

    The agreement involves transfer of these two marketing divisions along with employees to Strides for a consideration of Rs 165 crore Strides Shasun has received Competition Commission of India (CCI’s) approval to acquire Sun Pharmaceutical’s two business divisions in India for Rs 165 crore. In September last year, Sun Pharma and Strides signed an agreement […]

  • Strides Shasun gets CCI nod to buy Sun Pharma’s two divisions

    In September last year, Sun Pharma and Strides signed an agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions that are into central nervous system (CNS) segment in India.

  • Maintain ‘equalweight on Sun Pharma: Morgan Stanley

    The FDA uploaded the Halol Warning Letter (WL) on its website, detailing various observations (i.e. cGMP deviations) cited during the Sep’14 inspection…

  • Hold rating on Sun Pharma; Halol warning could delay recovery

    Post issuance of the warning letter, approvals from Halol will continue to be withheld, which will impact future launches from the facility

  • Sun Pharma, Sun Pharma shares, Sun Pharma managing director
    Sun Pharmaceutical raises Rs 1,000 cr via NCDs

    Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has raised, on private placement basis, Rs 1,000 crore by allotment of 10,000 unsecured redeemable non-convertible debentures of a face value of Rs 10,00,000 each.

  • Sun Pharma divests US manufacturing unit

    Divests Bryan unit to Nostrum Laboratories Sun Pharmaceutical Industries announced that as a part of its manufacturing consolidation in the US, one of its wholly-owned subsidiaries has entered into an agreement with Nostrum Laboratories (Nostrum) for the divestment of the Bryan (Ohio) unit in the US. As a part of the agreement, the Sun Pharma […]

  • Sun Pharma to sell US-based manufacturing unit to Nostrum Lab

    Drug major Sun Pharma today said it has sold its manufacturing unit in Ohio to Nostrum Laboratories Inc for an undisclosed sum as part of the company’s consolidation of manufacturing business in the US.

  • Maintain ‘neutral’ on Sun Pharma, target Rs 817: Nomura

    Sun Pharma (SUNP) announced approval for gGleevec on December 4, 2015. SUNP will launch gGleevec on February 1, 2016 with 180-day exclusivity.

  • Sun Pharmaceuticals
    Sun Pharmaceutical’s tender offer for InSite ends; to directly acquire shares

    Sun Pharmaceutical Industries today said its arm Thea Acquisition Corp plans to exercise a ‘top up option’ to purchase shares directly from eyecare firm InSite Vision to hold 90 per cent stake in the US-based company to complete a merger, after failing to get required number of shares via a tender offer.

  • Sun Pharma seeks shareholders’ approval on Rs 50,000 cr provision

    The company is also seeking an extension of an enabling resolution to raise up to Rs 12,000 crore via domestic and/or international capital markets Sun Pharmaceutical is seeking approval of its shareholders through a postal ballot earmarking of up to Rs 50,000 crore for the purpose of acquisitions or providing loans, among others. The Mumbai-based […]

Horoscope: By Peter Vidal

Today ( 24 Mar )This Week ( 18 Mar - 31 Mar )